Immunitybio Inc (IBRX) financials
Immunitybio revenue and earnings by year
Immunitybio's revenue was $113 million in the fiscal year to December 31, 2025, up 668.3% from the year before. Net income was -$351 million, -310.2% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 139.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113 | 15 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 0 |
| Revenue growth | 668.3% | 2270.6% | 159.2% | -74.3% | 54.4% | -72.5% | 4585.1% | 4.4% | 2.3% | — |
| Operating income | -256 | -344 | -362 | -351 | -330 | -221 | -156 | -98 | -99 | -125 |
| Operating margin | -226.0% | -2334.2% | -58239.5% | -146374.2% | -35361.9% | -36509.1% | -7095.9% | -209338.3% | -220266.7% | -282954.5% |
| Net income | -351 | -414 | -583 | -417 | -347 | -222 | -158 | -96 | -96 | -121 |
| Net margin | -310.2% | -2804.8% | -93761.4% | -173569.6% | -37129.6% | -36669.6% | -7165.2% | -204736.2% | -214273.3% | -274565.9% |
| Diluted EPS | -$0.38 | -$0.62 | -$1.15 | -$1.04 | -$0.89 | -$0.59 | — | -$1.22 | -$1.20 | -$1.47 |
| Free cash flow | -309 | -398 | -397 | -416 | -287 | -173 | -156 | -76 | -84 | -45 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open IBRX in Markets.
How Immunitybio makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Product | $50.7M | 98.9% |
| Product & Service Other | $568K | 1.1% |
See also: IBRX returns
No forecast, no recommendation. This page describes Immunitybio Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.